Trial Condition(s):

Carcinoma, Hepatocellular

INSIGHT - Post Marketing Surveillance (INSIGHT)

Bayer Identifier:

14690

ClinicalTrials.gov Identifier:

NCT00792350

EudraCT Number:

Not Available

Study Completed

Trial Purpose

In this international non-interventional post-marketing surveillance study we want to evaluate patient characteristics in HCC patients as well as efficacy and safety of Sorafenib (Nexavar®) treatment under daily-life treatment conditions. Specifically investigated are the tumor status, prior and/ or concomitant surgical, radiological and drug treatment and the duration of Sorafenib treatment.

Inclusion Criteria
- In- and outpatients with diagnosis of  hepatocellular carcinoma (HCC) and decision taken by the investigator to prescribe Nexavar
Exclusion Criteria
- Exclusion criteria must be read in conjunction with the local product information

Trial Summary

Enrollment Goal
791
Trial Dates
black-arrow
Phase
N/A
Could I receive a placebo?
No
Products
Nexavar (Sorafenib, BAY43-9006)
Accepts Healthy Volunteers
No

Where to Participate

Loading...
Locations
Status
LocationsStatus
Locations

Investigative Site

Many Locations, Germany

Status
Completed
 
Locations

Investigative Site

Many Locations, Austria

Status
Completed
 

Trial Design